Welcome to Cardiology Today – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding. Article Links: Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. (Circulation) Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (European heart journal) Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. (European heart journal) Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. (European heart journal) Article 5: Clonal Hematopoiesis and Incident Heart Failure. (JAMA cardiology) Full episode page: https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/ Featured Articles Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206792 Summary: The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management. Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206679 Summary: The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices. Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796244 Summary: The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population. Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. Journal: European heart journal PubMed Link: https://pubmed